Amiko

What Amiko does

Amiko (Amiko Srl) is a Milan-based medical-technology company founded in 2015 that builds Respiro, a full-stack connected respiratory care platform for inhaled medicine. The product spans hardware inhaler sensors, a regulated cloud data layer, and patient and clinician applications that capture dose timing, inhalation technique, and breathing-risk signals from everyday inhaler use. The hardware layer includes the RS01X, a fully integrated connected inhaler co-developed with Plastiape using its RS01 capsule DPI platform with Respiro sensing embedded, plus add-on clip-on sensor modules for RS01, pMDI, and GSK Ellipta inhalers. Amiko's algorithms convert raw inhalation signals into adherence scores, technique assessments, and personalised breathing-risk forecasts, with measurement accuracy validated at ICC >0.95 against laboratory reference. The company is ISO 13485:2016 certified, CE-marked under EU MDR, GDPR-compliant, and HIPAA-ready for US deployments.

Amiko monetises through four revenue streams: connected inhaler hardware sales (RS01X and add-on sensors manufactured by Plastiape), SaaS subscriptions to the Respiro platform, clinical trial services providing digital endpoints and audit-ready data for pharma-sponsored studies, and white-label/SDK licensing for partners embedding connected-respiratory intelligence in their own products. The go-to-market is a multi-channel enterprise sales motion targeting four primary segments: pharmaceutical companies (connected drug delivery, real-world evidence, market access), healthcare providers (respiratory RPM and clinic-ready dashboards), digital-health partners (SDK/API integration and white-label apps), and academic/clinical researchers. Distribution blends direct enterprise field sales, partner-first integration via REST APIs and an iOS/Android Connect SDK, and pharmacy-led service pilots across Italy, the Netherlands, Portugal, and Germany.

The company has secured strategic investment from Sanner Ventures and Breed Reply (January 2018) and has drawn non-dilutive funding from Italian and EU public programmes including POR FESR Tech Fast Lombardia (November 2021) and the PNRR-funded ARTES 4.0 RESPIRO project (2024-2025). Clinical evidence includes a cluster RCT across 18 pharmacies presented at ERS 2022 (+5.9 ACT points vs +2.9 control, p=0.007; €466 annual cost saving per patient, p=0.04) and a 2025 RS01X validation study. Amiko remains privately held with no disclosed parent company or subsequent equity round, operating from a fully remote team of 11-50 employees.

Name

Amiko

Legal name

Amiko Srl

Website

https://amiko.io

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Amiko builds Respiro, a connected respiratory care platform combining smart inhaler sensors, a regulated cloud data layer, and patient/clinician apps, serving pharmaceutical companies, healthcare providers, digital-health partners, and clinical researchers across Europe.

Ownership category

akta.pro rank

Product category

Connected Respiratory Care / Digital Health Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH)

akta.pro secondary industries

Respiratory & Sleep RPM (COPD, asthma, sleep apnea) (HLALAFAB), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories) (HLAHAGAE)

Keywords

• Connected inhaler platform
• Digital respiratory medicine
• Smart inhaler sensors
• Medical device software
• Respiratory adherence monitoring

Headquarters

HQ city

Milan

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Connected Inhaler Hardware Sales: Sale of RS01X connected inhalers (fully integrated) and add-on smart inhaler sensors co-developed with Plastiape. Device manufacturing by Plastiape; sensing and connectivity by Amiko.
2. Respiro Platform Subscription: SaaS subscription to the Respiro platform including patient app, clinician dashboard, regulated cloud, and data APIs. Powers connected inhaler programmes for pharma, providers, and partners.
3. Clinical Trial Services: Trial-grade data services for pharma-sponsored and investigator-led respiratory clinical trials. Digital endpoints, eCOA-ready measures, and audit-ready source data for connected, decentralised trial designs.
4. Digital Health Technology Licensing: White-label Respiro-powered apps and SDK licensing for partners wanting to embed connected-respiratory intelligence in their own branded products or platforms.

Go-to-market motion5 records

Distribution channels5 records

Marketing channels5 records

Core offering

Amiko sells Respiro, a connected respiratory care platform that turns inhaler use into clinical intelligence. Its core deliverable is the Respiro stack: smart inhaler sensors (including the RS01X connected inhaler co-developed with Plastiape and clip-on add-on sensors), a regulated medical-device cloud (ISO 13485, GDPR, EU MDR CE-marked), and a patient app plus clinician dashboard that surface adherence, inhalation-technique scores, breathing-risk forecasts, and real-world evidence for pharma, healthcare providers, and digital-health partners.

Product overview

Amiko builds Respiro, a connected respiratory platform for inhaled medicine, delivered as a layered system of hardware sensors, a regulated cloud intelligence layer, and patient/clinician-facing surfaces. The hardware layer includes the RS01X (an integrated connected inhaler built on Plastiape's RS01 capsule DPI with Respiro sensing embedded) and a range of add-on clip-on sensor modules for RS01 capsule, pMDI and Ellipta inhalers. The regulated cloud (Respiro core) turns raw inhalation signals into adherence scores, inhalation-technique scoring and a personalised breathing-risk forecast. On top of the cloud sit the Respiro patient app, a clinician dashboard, and real-world evidence outputs for pharma. Partners can also embed Respiro's data via REST APIs, webhooks and an iOS/Android Connect SDK (Respiro Connect), or white-label the full patient/clinician experience. The platform serves pharma (connected drug delivery, clinical trials, RWE), providers (respiratory RPM), and digital-health partners.

Differentiator

Problem solved

Functional benefit

Products and services

• Respiro Platform End-to-end connected respiratory care platform: smart inhaler sensors, a regulated medical-device cloud (ISO 13485, GDPR, CE under EU MDR), patient app and clinician dashboard that capture dose timing, inhalation quality, adherence, technique, and breathing-risk forecasts. Sold to pharma, healthcare providers, and digital-health partners.
• RS01X Connected Inhaler Fully integrated connected capsule dry-powder inhaler built on Plastiape's RS01 platform with Respiro sensing embedded; captures dose and inhalation quality (duration, volume, peak inspiratory flow) without changing patient routine. Sold to pharma partners and clinical programmes.
• Add-on Smart Inhaler Sensors Clip-on sensor modules that attach to RS01 capsule DPIs, pressurised metered-dose inhalers (pMDI), and GSK Ellipta multi-dose DPIs, bringing Respiro adherence and inhalation-quality capture to inhalers already in patients' hands without changing the core delivery device.
• Respiro Connect (SDK and API) Integration layer for the Respiro platform: iOS and Android JavaScript Connect SDK plus REST APIs and webhooks that let digital-health, telehealth, and device partners embed adherence, technique, and breathing-risk signal inside their own products.
• Respiro Regulated Cloud and Core Algorithms ISO 13485-certified, GDPR-aligned regulated cloud with proprietary algorithms that turn raw inhaler signals into adherence scores, inhalation-technique assessment, and personalised breathing-risk forecasts. Supports HIPAA-ready deployments with Business Associate Agreements.
• Respiro Patient App Patient-facing mobile companion app that tracks every dose with timing and technique, delivers a daily breathing-risk forecast, and shares a clinician-ready history for consultations.
• Respiro Clinician Dashboard Care-team-facing dashboard with exacerbation-risk flags, pre-visit adherence and technique summaries, and exportable reports supporting respiratory remote patient monitoring workflows.
• Real-World Evidence Service for Pharma Device-linked adherence and inhalation-quality evidence for pharma partners supporting development, market access dossiers, outcomes-based access agreements, and launch differentiation with data that claims records cannot provide.
• Digital Endpoints and Clinical Trial Services Trial-grade dose, technique and inhalation data delivered as digital endpoints and eCOA-ready measures for connected and decentralised respiratory clinical trials, with audit-ready source records and structured data exports for pharma sponsors and CROs.
• Respiratory Remote Patient Monitoring (RPM) Programme Respiro-powered RPM programme for healthcare providers that automatically captures inhaler dose timing and technique, feeds a prioritised care queue with exacerbation-risk flags, and delivers clinic-ready summaries for pre-visit review.
• White-Label Respiro App Fully branded patient and clinician experience powered by Respiro underneath, available to partners who want to launch connected-respiratory products under their own brand quickly.

Quantifiable outcome

• +5.9 asthma control points (ACT improvement vs +2.9 with usual care, p=0.007)
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Partnerships

Six partnerships are on record, tiered core, flagship and minor.

• ARTES 4.0coreStrategic or Co-development Partner · 1 February 2024PNRR-funded R&D project (PIATTAFORMA RESPIRO 2024-2025) integrating CFD simulation and automation into next-generation inhaler sensor development. 18-month project aiming for 40% reduction in concept-to-production timeline. Part of Line 'Sviluppo di Progetti di Innovazione' under Mission 4 Component 2 of Italy's PNRR.
• SIDERA^B Consortium (Regione Lombardia)coreStrategic or Co-development Partner · 1 January 2022Regione Lombardia funded initiative for integrated home care and assisted rehabilitation. Amiko contributes connected respiratory support for COPD patients alongside consortium partners including Telbios, IRCCS Fondazione Don Carlo Gnocchi, Politecnico di Milano, Università degli Studi di Milano – Bicocca, LIUC – Università Cattaneo, Grifo multimedia, and Tenacta Group. Total project €6.37M with €3.28M grant.
• PlastiapeflagshipOEM/ Whitelabel/ Licensing Partner · 1 December 2020Global commercial agreement to launch RS01X: the connected evolution of Plastiape's widely used RS01 single-dose inhaler with Respiro built in. Plastiape handles device development, manufacturing, and supply at commercial scale; Amiko runs digital services and the Respiro platform. Manufacturing in ISO 7 (Class 10,000) clean rooms.
• ReplyminorStrategic or Co-development Partner · 1 May 2019Partnership through the ACT4Y initiative with Reply and University of Twente. Built a digital prescription-intervention service combining inhaler sensors, usage data, and pulmonary-pharmacist support for asthma management.
• University of TwenteminorStrategic or Co-development Partner · 1 May 2019Academic partner in ACT4Y initiative alongside Reply, developing digital prescription-intervention service for asthma with objective adherence and technique data.
• Luz SaúdecoreStrategic or Co-development Partner · 1 July 2018Partnership with Portugal's largest healthcare group to bring connected respiratory monitoring into routine asthma and COPD care. Respiro inhaler sensors capture inhalation data for personalised medication reviews that care teams can act on, bringing respiratory care into the digital age.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Propeller Health (ResMed): Direct competitor in connected-inhaler sensors and adherence platforms; acquired by ResMed in 2019 and now partners with GSK, Boehringer Ingelheim and Vectura/Novartis on connected respiratory programmes. Most directly comparable in product, target customers (pharma and providers) and business model.
• Adherium: Smart-inhaler sensor company with Hailie sensors for asthma and COPD adherence monitoring, selling to pharma and providers. Direct competitor with overlapping add-on sensor product, similar clinical-evidence-led GTM and similar respiratory adherence focus.
• FindAir: European (Polish) connected-inhaler company offering smart inhaler sensors and a respiratory disease management app, also targeting pharma and providers. Closely comparable to Amiko in geography, product scope and asthma/COPD use cases, though with a more consumer-leaning app model.

Emerging players

• Cohero Health: Connected respiratory platform with smart inhaler sensors and a clinician dashboard for asthma and COPD management. Comparable in product surface and customer segments, though smaller and more US-focused than Amiko.

Broad incumbents

• Teva Pharmaceutical Industries (Digihaler line): Teva markets Digihaler, a portfolio of built-in connected inhalers with companion app. A large incumbent pharma competitor that already has CE marks on multiple connected inhalers (including Spiromax, which Amiko's add-on sensors also support) and competes for the same pharma RWE and digital companion budget.
• Aptar Pharma: Global drug-delivery device manufacturer (pMDIs, DPIs, nasal) with a growing digital health and connected-device portfolio. Comparable as a partner/competitor for inhaler device platforms and a natural commercial partner or acquirer in connected respiratory.
• Vectura (Philip Morris International): Inhaled drug-delivery device platform with DPI and pMDI technology and a digital health programme, now part of Philip Morris International. Comparable as a broad incumbent inhaler device competitor that also partners with Propeller Health and others on connected respiratory programmes.

Others

• Plastiape (part of Berry Global / Amcor): Amiko's flagship OEM partner for RS01X; manufacturer of the RS01 single-dose DPI and other inhaled drug delivery devices. Included as a peer/partner given the deep commercial and product interdependence around the RS01X connected inhaler.
• Sanner Group: Drug-delivery and medical-packaging group that led Amiko's 2018 strategic round via Sanner Ventures. Comparable as an adjacent device-and-packaging player in inhaled drug delivery and active corporate investor in connected respiratory care.
• Sensirion: Sensor manufacturer whose flow and pressure sensors are widely used in smart inhalers and respiratory devices. Adjacent technology peer and potential supplier/competitor in the underlying sensor layer that powers connected-inhaler accuracy claims.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/amiko_io
• LinkedInlinkedin.com/company/amiko

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amiko